ClinicalTrials.gg
CompletedNCT03206970Updated Oct 26, 2024Results posted

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Phase 2 interventional study of Zanubrutinib in Refractory Mantle Cell Lymphoma and Relapsed Mantle Cell Lymphoma, sponsored by BeiGene. Completed at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2017, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell — 12 open to participants now, 14 under way, 2 of them phase 3. zanubrutinib · Lymphoma, Mantle-Cell.

Enrollment
4th of 17
86 · median 45
Started
2017
the only one that year
Phase 2
13 of 17
10 open now
Registered
1st of 17
by date
Lead sponsor
3 of 17
BeiGene

Among the 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 13 in phase 2, and was the 1st registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

12 of the 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell are open now, in 4 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.

03

Conditions studied

  • Refractory Mantle Cell Lymphoma
  • Relapsed Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnostic report had to include evidence for morphological and cyclin D1 or t (11; 14).
  2. performance status of 0-2.
  3. by computed tomography/magnetic resonance imaging.
  4. Received prior regimens for MCL.
  5. Documented failure to achieve any response, (stable disease or progressive disease during treatment) or documented progressive disease after response to the most recent treatment regimen.
  6. and alanine aminotransferase ≤ 2.5 x (ULN).
  7. Total ≤ 2 x ULN (unless documented Gilbert's syndrome).
  8. of > 4 months.

Key Exclusion Criteria:

  1. Current or history of central nervous system lymphoma.
  2. Prior exposure to a BTK inhibitor before enrollment.
  3. Prior with anti-neoplastic intent within 7 days.
  4. Major surgery within 4 weeks of screening.
  5. Toxicity must have recovered from prior chemotherapy.
  6. History of other active within 2 years of study entry.
  7. Currently active cardiovascular disease.
  8. corrected with Fridericia's formula > 450 microseconds or other significant abnormalities.
  9. Uncontrolled systemic infection or infection requiring parenteral anti-microbial therapy.
  10. Known infection, or active or infection (detected positive by polymerase chain reaction).

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Zanubrutinib (160 milligrams) administered orally twice daily

    Drug: Zanubrutinib

Interventions

  • Administered as specified in the treatment arm.

    Also known as: BGB-3111

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) As Assessed By Independent Review Committee

    The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR.

    Time frame: Up to 1 year and 11 months

Secondary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from the starting date of zanubrutinib to the date of first documentation of disease progression or death, whichever occurred first. Participants who did not have disease progression were censored at their last valid tumor assessment. A six-month progression-free survival rate was defined as no disease progression after treated with zanubrutinib for over six months (under control). The 95% confidence interval (CI) lower bound was 33.1 months while the upper bound could not be estimated.

    Time frame: Up to 3 years and 6 months

  2. Time To Response

    Time to response was defined as the time from treatment initiation to the first documentation of response.

    Time frame: Up to 3 years and 6 months

  3. Duration Of Response

    The duration of response was defined as the time from the date that the response criteria are first met to the date that Progressive Disease was objectively documented or death (whichever occurs first). Participants who did not have disease progression were censored at their last valid assessment.

    Time frame: Up to 3 years and 6 months

  4. ORR As Assessed By The Investigator

    The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a BOR of CR or PR. The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR. For this outcome measure, only investigator-assessed data are analyzed and reported because of the high rate of concordance between the Independent Review Committee and investigator assessments for the primary outcome measure of ORR.

    Time frame: Up to 3 years and 6 months

  5. Number Of Participants Experiencing Treatment -Emergent Adverse Events (AEs)

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. A treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up visit) or initiation of new anticancer therapy, whichever comes first.

    Time frame: From the initiation of study drug until 30 days after the last dose (Up to 3 years and 6 months)

  6. Number Of Participants Experiencing AEs Leading To Treatment Discontinuation

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to the study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: From the initiation of study drug until 30 days after the last dose (Up to 3 years and 6 months)

07

Results

Posted May 13, 2020

Participant flow

This study was conducted at 14 study centers in China; 13 study centers enrolled participants. Once the primary and secondary objectives were met and the analysis was complete, sponsor ended the study on 08 September 2020 and transferred all participants remaining on treatment to long term extension study.

Participant flow — Overall Study
MilestoneZanubrutinib
Started86
Received at least 1 dose of study drug86
Completed0
Not completed86
Withdrew: Death21
Withdrew: Withdrawal by subject13
Withdrew: Lost to follow-up3
Withdrew: Primary and secondary objectives were met and remaining participants transferred to lte by sponsor49

Outcome measures

PrimaryOverall Response Rate (ORR) As Assessed By Independent Review Committee

The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR.

Time frame:
Up to 1 year and 11 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) As Assessed By Independent Review Committee
ParticipantsZanubrutinib
Overall Response Rate (ORR) As Assessed By Independent Review Committee72
Statistical analysis
  • Zanubrutinib · Binomial Exact Test · p = <.0001 · Clopper-pearson: 83.7 · 95% CI 74.2 to 90.8
SecondaryProgression-free Survival

Progression-free survival was defined as the time from the starting date of zanubrutinib to the date of first documentation of disease progression or death, whichever occurred first. Participants who did not have disease progression were censored at their last valid tumor assessment. A six-month progression-free survival rate was defined as no disease progression after treated with zanubrutinib for over six months (under control). The 95% confidence interval (CI) lower bound was 33.1 months while the upper bound could not be estimated.

Time frame:
Up to 3 years and 6 months
Reported as:
Median · months
Progression-free Survival
monthsZanubrutinib
Progression-free Survival33.0 (19.4 to NA)
SecondaryTime To Response

Time to response was defined as the time from treatment initiation to the first documentation of response.

Time frame:
Up to 3 years and 6 months
Reported as:
Mean · months
Time To Response
monthsZanubrutinib
Time To Response2.72 ± 0.105
SecondaryDuration Of Response

The duration of response was defined as the time from the date that the response criteria are first met to the date that Progressive Disease was objectively documented or death (whichever occurs first). Participants who did not have disease progression were censored at their last valid assessment.

Time frame:
Up to 3 years and 6 months
Reported as:
Median · months
Duration Of Response
monthsZanubrutinib
Duration Of ResponseNA (24.9 to NA)
SecondaryORR As Assessed By The Investigator

The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a BOR of CR or PR. The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR. For this outcome measure, only investigator-assessed data are analyzed and reported because of the high rate of concordance between the Independent Review Committee and investigator assessments for the primary outcome measure of ORR.

Time frame:
Up to 3 years and 6 months
Reported as:
Count of participants · Participants
ORR As Assessed By The Investigator
ParticipantsZanubrutinib
ORR As Assessed By The Investigator72
Statistical analysis
  • Zanubrutinib · Binomial Exact Test · p = <0.0001 · Clopper-pearson: 83.7 · 95% CI 74.2 to 90.8
SecondaryNumber Of Participants Experiencing Treatment -Emergent Adverse Events (AEs)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. A treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up visit) or initiation of new anticancer therapy, whichever comes first.

Time frame:
From the initiation of study drug until 30 days after the last dose (Up to 3 years and 6 months)
Reported as:
Count of participants · Participants
Number Of Participants Experiencing Treatment -Emergent Adverse Events (AEs)
ParticipantsZanubrutinib
Number Of Participants Experiencing Treatment -Emergent Adverse Events (AEs)83
SecondaryNumber Of Participants Experiencing AEs Leading To Treatment Discontinuation

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to the study drug or not. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
From the initiation of study drug until 30 days after the last dose (Up to 3 years and 6 months)
Reported as:
Count of participants · Participants
Number Of Participants Experiencing AEs Leading To Treatment Discontinuation
ParticipantsZanubrutinib
Number Of Participants Experiencing AEs Leading To Treatment Discontinuation8

Adverse events

Collected over Day 1 through 3 years and 6 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib7/86 (8.1%)25/86 (29.1%)82/86 (95.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventZanubrutinib
PneumoniaInfections and infestations10/86
Upper gastrointestinal haemorrhageGastrointestinal disorders2/86
DeathGeneral disorders2/86
Platelet count decreasedInvestigations2/86
AnaemiaBlood and lymphatic system disorders1/86
Bone marrow necrosisBlood and lymphatic system disorders1/86
Gastrointestinal haemorrhageGastrointestinal disorders1/86
BronchitisInfections and infestations1/86
InfectionInfections and infestations1/86
Pneumonia fungalInfections and infestations1/86
Most frequent other events
Showing 10 of 49
Most frequent other events
EventZanubrutinib
Neutrophil count decreasedInvestigations39/86
Upper respiratory tract infectionInfections and infestations33/86
RashSkin and subcutaneous tissue disorders31/86
White blood cell count decreasedInvestigations29/86
Platelet count decreasedInvestigations28/86
Alanine aminotransferase increasedInvestigations16/86
HypokalaemiaMetabolism and nutrition disorders15/86
AnaemiaBlood and lymphatic system disorders14/86
DiarrhoeaGastrointestinal disorders14/86
HypertensionVascular disorders13/86

Baseline characteristics

Safety Analysis Set: All participants who received any dose of study drug.

Age, Continuous
Age, Continuous(years)Zanubrutinib
Mean59.0 ± 8.18
Age, Customized
Age, Customized(Participants)Zanubrutinib
< 65 years64
≥ 65 years22
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib
Female19
Male67
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zanubrutinib
Chinese86
Region of Enrollment
Region of Enrollment(participants)Zanubrutinib
China86
Mantle Cell Lymphoma (MCL) Disease Stage at Study Entry
Mantle Cell Lymphoma (MCL) Disease Stage at Study Entry(Participants)Zanubrutinib
MCL Stage I1
MCL Stage II7
MCL Stage III14
MCL Stage IV64
Disease Status
Disease Status(Participants)Zanubrutinib
Relapsed Disease41
Refractory Disease45
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(Participants)Zanubrutinib
Grade 060
Grade 122
Grade 24
08

Study locations

13 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin 300020, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Haiyi Guo, Aihua Wang, James Hilger, Jane Huang, William Novotny, Muhtar Osman, Jun Zhu; Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial. Blood 2018; 132 (Supplement 1): 148. doi: https://doi.org/10.1182/blood-2018-99-117956
  • Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Elstrom R, Huang J, Novotny W, Wei R, Zhu J. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clin Cancer Res. 2020 Aug 15;26(16):4216-4224. doi: 10.1158/1078-0432.CCR-19-3703. Epub 2020 May 27. PubMed 32461234 ↗
  • Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021 Jun 22;5(12):2577-2585. doi: 10.1182/bloodadvances.2020004074. PubMed 34152395 ↗
  • Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Huang J, Novotny W, Kim P, Yu Y, Wu B, Zhu J. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022 May 26;139(21):3148-3158. doi: 10.1182/blood.2021014162. PubMed 35303070 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Feb 2019, 23 months.

Results were first posted in May 2020, 1 year 2 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 23 months is below that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2017
First posted
Jul 2, 2017
StartActual
Mar 2, 2017
Primary completionActual
Feb 15, 2019
CompletionActual
Sep 8, 2020
Results first posted
May 13, 2020
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03206970
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Mar 2, 2017
Primary completion
Feb 15, 2019
Completion
Sep 8, 2020
Results posted
May 13, 2020
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion